Sentences with phrase «lung cancer among»

Radon is the No. 1 cause of lung cancer among nonsmokers.

I have seen many more cases of lung cancer among nonsmokers than smokers in the thousands of patients I have cared for over the past thirty years, but that doesn't negate the studies done on the subject that show only about 15 % of lung cancer cases occur in nonsmokers.

As the Colorado State study reported, «there was a slightly higher incidence of lung cancer among the short / medium nosed dogs.

Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women.

Similarly, a Japanese population study of over 75 thousand men and women found a decreased risk of lung cancer among people who consumed soy products on a regular basis (Isoflavone intake and risk of lung cancer: a prospective cohort study in Japan.

However, in subgroup analyses stratified by age, we found that the deletion allele was associated with increased risk for lung cancer among individuals < 50 years of age (OR 2.17, CI 1.19 - 3.97), and that the association was gradually reduced with increasing age (p = 0.01).

Although smoking is the main risk factor, adenocarcinoma is also the most common type of lung cancer among lifelong non-smokers, and the risk of lung cancer is increased by 20 to 30 percent by exposure to secondhand smoke.

«Lung Cancer Among Navajo Uranium Miners,» Leon S. Gottlieb, M.D., F.C.C.P., and Laverne A. Husen, M.D., CHEST, Volume 81:4, April 1982.

«We observed a 49 percent increased risk of lung cancer among subjects with the highest daily GI compared to those with the lowest daily GI,» says senior author Xifeng Wu.

A higher rate of lung cancer among men who had had vasectomies more than 20 years earlier was offset by a lower rate of cardiovascular disease.

The overall death rate for lung cancer among women is being driven by women in the UK and Poland, with predicted rates of 21 and 17 per 100,000 in the UK and Poland respectively.

«We observed a 49 percent increased risk of lung cancer among subjects with the highest daily glycemic index,» author of new study says.

Not exact matches

Mount Sinai in NY is among the first to test a personalized vaccine for lung, breast, gynecological and bladder cancers.

The measure has the backing of the Roswell Park Cancer Institute and the American Lung Association, among other medical groups.

These include 46,000 heart attack deaths and 3,400 lung cancer deaths among nonsmokers who are exposed to secondhand smoke.

Among the groups joining the Cancer Society in the effort are the American Lung Association and The Campaign for Tobacco Free Kids.

Since 1972, the proportion of deaths among women due to lung cancer has increased from 10 % to 22 % — a figure backed up by the latest results from Statistik Austria.

Aaron P. Mitchell, M.D., of the University of North Carolina at Chapel Hill School of Medicine, and coauthors examined FCOIs during 2014 among 125 authors of the guidelines for the treatment of breast, colon, prostate and lung cancer because those are the cancers with the highest incidence in the U.S.

«In view of the fact that lung cancer has now overtaken breast cancer as the commonest cause of death from cancer among women, that is alarming.

For instance, among the six largest countries, although the actual numbers of female deaths from lung cancer will still be the highest in the UK in 2016 than in the other large countries (at 16,400), the rate per 100,000 women has started to fall (from 20.15 per 100,000 in 2013 to 19.37 predicted in 2016), while death rates are still rising in the other countries.

On the other hand, the continuing increase in lung cancer mortality among European women represents a challenge for cancer control, and the steady increase in pancreatic cancer deserves high priority for research.»

The first, a cohort - analysis paper run by NIOSH, looked at all deaths among the miners, from lung cancer as well as other causes.

These rates are more than double those in Spain, which has a lung cancer death rate among women of just over eight per 100,000.

Among other tests, they looked at tissue samples of breast cancer that had spread to the liver, lung and other organs.

Among patients who have this type of lung cancer, nearly one in three will carry a particular genetic mutation on their cancer cells.

To understand the complex relationship among the miRNA let - 7, the KRAS gene and the KRAS protein, Slack decided to look at how they interacted in lung cancer.

This pre-clinical study from Professor Mazzone and his colleagues reveals a new molecular axis that may offer interesting therapeutic opportunities for the treatment of pancreatic cancer, breast cancer and lung cancer, among others.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

These results are among the best in the field, offering a lot of hope to people with ALK - positive lung cancer,» says D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado Cancer Center and the trial's principal investicancer,» says D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado Cancer Center and the trial's principal investiCancer Center and the trial's principal investigator.

Researchers at the Menzies Centre for Population Health Research in Hobart have found that in Tasmania between 1983 and 1992, there were almost twice as many lung cancer cases among women aged between 25 and 44 years as in men of the same age.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

Among patients with metastatic lung cancer, comorbidity had less impact on survival.

The research team accounted for the impact of smoking among the participants, since people who smoke are more likely to get periodontal disease, and smoking raises the risk of lung and colon cancers.

Islam and colleagues found that among patients with localized lung cancer, those with one comorbidity had a 30 percent higher risk of mortality compared with those who had no comorbidity.

While lung cancer is the leading cause of cancer death and the second most commonly diagnosed cancer in both men and women, a low survival rate makes it the number eight cancer site represented among survivors.

In 2015, Tomasetti and Vogelstein published a widely covered Science paper that found that R mutations explain the dramatic variation in cancer incidence among human tissues better than hereditary or environmental factors — helping to illuminate why tissues in the lung or colon give rise to cancer far more frequently than tissues in bone or brain, for example.

Among lung cancer patients, Asians have a more than 13-fold and men a nearly 9-fold increase in suicides.

Among lung cancer patients; suicide SMR was higher in males (SMR = 8.8), Asians (SMR = 13.7), widowed patients (SMR = 11.6), older patients (70 - 75 years; SMR = 12), patients with undifferentiated tumors (SMR 8.6) or small cell lung carcinoma (SCLC) histology (SMR = 11.2), patients presenting with metastatic disease (SMR = 13.9) and in patients who refused to receive surgical treatment (SMR = 13).

Suicide risk is highest among lung cancer patients, particularly older patients, widowed, males, and patients with unfavorable tumor characteristics.

The most common causes of deaths related to smoking among people in prison were lung cancer, heart disease, stroke, and chronic lung disease.

The consensus on human - caused climate change is among the strongest observed in the sciences — about as strong as the consensus surrounding the link between smoking and lung cancer.

«Understanding the differences among lung cancers also could lead to innovations in treatment strategies and allow us to overcome drug - resistance, relapse and disease progression.»

However, rates continue to increase among older women in many countries, indicating a need for more concentrated efforts to initiate or expand comprehensive tobacco control programs across the globe to curtail future tobacco - related lung cancer deaths.

Lung cancer mortality rates among young women (30 - 49 years) were stable or declining in 47 of the 52 populations examined.

Lung cancer mortality rates (per 100,000) during 2006 - 2010 ranged from 0.7 in Costa Rica to 14.8 in Hungary among young women and from 8.8 in Georgia to 120.0 in Scotland among older women.

Among others, RET plays a role in around 50 percent of medullary thyroid cancers, 20 percent of papillary thyroid cancers, and up to two percent of non-small cell lung cancers.

Researchers find BCX — red pigment abundant in sweet red peppers, paprika, winter and butternut squash, oranges, and tangerines, among other foods — appears to counteract nicotine's ability to accelerate the growth of lung tumors.Photo credit: IngimageXiang - Dong Wang, a cancer researcher at Tufts University, has spent a long time trying to figure out why carotenoids, the main pigments providing colors that range from yellow and pink to deep orange and red in most fruits and vegetables, seem to keep chronic diseases at bay.

When a 2004 study by other researchers showed that eating foods containing beta - cryptoxanthin (BCX)-- a red pigment abundant in sweet red peppers, paprika, winter and butternut squash, oranges, and tangerines, among other foods — was associated with a lower risk of lung cancer in people who smoke, he made BCX a focus of his research.

Immunotherapy using checkpoint inhibitors has changed the way we treat several aggressive cancers such as melanoma, non-small cell lung and head & neck cancers, among others, with durable responses achieved in the metastatic setting.

An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with results from a phase I trial showing that, among 236 patients with various types of cancer, the treatment shrank tumors in 28 percent of melanoma patients, 30 percent of patients with kidney cancer, and 18 percent of patients with advanced non-small cell lung cancer.